The effects of androstanediol and estradiol on prostatic growth were investigated in castrate dogs. Estrogens along resulted in no significant change in prostatic weight, whereas androstanediol produced growth comparable to that in uncastrated controls. Androstanediol plus estradiol resulted in an even more striking increase in prostate growth. Approximately half the animals receiving androstanediol alone and all of those receiving androstanediol plus estradiol fulfill the weight and histological criteria for prostatic hypertrophy in the dog. Since both these steroid hormones are presumed to be normal secretory products of the testis, it is possible that they are involved in the pathogenesis of prostatic hypertrophy in the dog.
P C Walsh, J D Wilson
Year: | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 | 1982 | 1981 | 1980 | 1979 | 1978 | 1977 | 1974 | 1970 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Citations: | 1 | 1 | 3 | 2 | 2 | 2 | 8 | 4 | 3 | 2 | 2 | 7 | 5 | 5 | 5 | 1 | 3 | 5 | 4 | 10 | 5 | 6 | 8 | 6 | 10 | 5 | 7 | 16 | 10 | 10 | 7 | 15 | 7 | 8 | 11 | 12 | 6 | 10 | 14 | 6 | 12 | 9 | 16 | 14 | 7 | 6 | 1 | 1 | 320 |
Title and authors | Publication | Year |
---|---|---|
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia
M Jiang, DW Strand, OE Franco, PE Clark, SW Hayward |
Differentiation | 2011 |
Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone
JL Mohler, MA Titus, EM Wilson |
Clinical cancer research | 2011 |
Estrogen and androgen signaling in the pathogenesis of BPH
CK Ho, FK Habib |
Nature Reviews Urology | 2011 |
Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer
JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih, KB Tomer, EM Wilson |
Cancer research | 2011 |
Transarterial Prostatic Embolization: Initial Experience in a Canine Model
F Sun, FM Sánchez, V Crisóstomo, I Díaz-Güemes, C López-Sánchez, J Usón, M Maynar |
AJR. American journal of roentgenology | 2011 |
Androgens and estrogens in benign prostatic hyperplasia: past, present and future
TM Nicholson, WA Ricke |
Differentiation | 2011 |
Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone: Figure 1
JL Mohler, MA Titus, EM Wilson |
Clinical cancer research | 2011 |